

For submission to the Extraordinary General Meeting of
Marinomed Biotech AG
to be held on December 19, 2024

Declaration pursuant to Section 87 (2) Austrian Stock Corporation Act (AktG)

In accordance with Section 87 (2) of the Austrian Stock Corporation Act (AktG), each person proposed for election to the Supervisory Board must disclose to the General Meeting their professional qualifications, their professional or comparable functions and any circumstances that could give rise to concerns over bias.

For a description of my professional qualifications and my professional or comparable functions, please refer to my attached curriculum vitae.

I therefore have the professional qualifications required to serve on the Supervisory Board of Marinomed Biotech AG.

Furthermore, I hereby declare that

1. I have disclosed all circumstances in connection with Section 87 (2) AktG and, in my opinion, there are no circumstances that could give rise to concerns over bias,
2. I have not been convicted of any criminal offence by a court of law, in particular of any offence that would call my professional reliability into question pursuant to Section 87 (2a) 3rd sentence AktG,
3. there are no obstacles to appointment within the meaning of Section 86 para. 2, in particular Section 86 para. 2 no. 1 in conjunction with Section 86 para. 3 AktG (exceeding the statutory maximum number of Supervisory Board mandates) and Section 86 para. 4 AktG,
4. I do not hold any directorships in other companies that are in competition with Marinomed Biotech AG, and
5. I have no business or personal relationship with Marinomed Biotech AG or its Management Board that constitutes a material conflict of interest and is therefore capable of influencing my conduct as a member of the Supervisory Board.

Enclosure: Curriculum vitae

Basel, on 27. November 2024



.....
Dr. Karl MAHLER

Note:

This is a working translation of the German language version and for convenience only. In the event of conflict with the German language version, the German language version shall prevail.

Dr. Karl Mahler

Married

2 children

Swiss and German citizen



- 1983 – 1987:** Ph.D. in Economics (Institute for Mathematical Economy), Univ. of Freiburg
- 1987 – 1992:** CH / Basel: Ciba Geigy: Head of Strategic and Investment Planning
- 1992 – 1995:** Germany / Freiburg: General Manager of the Tumor Biology Center in Freiburg i. Brsg. – founded the largest Cancer Research Clinic in Germany – an Institution consisting of a Clinic for Acute Treatment, Center for Oncological Rehabilitation, Basic Research, and Cancer Drug Development
- 1995 – 2000:** China / Shanghai & Beijing: General Manager of two Joint Ventures in Life Sciences (Animal Health- Shanghai /Novartis and Pharma- Beijing / Aventis)
Member of the Asia Executive Committee – Headquarters in Tokyo
- 2000 – 2002:** France / Strasbourg: Head of Planning, Deputy Head Investor Relations Aventis
- 2002 – 2022:** Basel: Hoffmann La Roche: Member of the Finance Leadership Team
(retirement)
- Head of Investor Relations - regular contact with all major Financial Market participants and institutions on the equity and debt side, a key member of the Genentech acquisition (largest cash transaction so far / financing in mid of Lehman crisis), the transfer of the Roche shares from Novartis to Roche (largest Swiss capital market transaction), and many other M&A transactions, Roche with strong market cap development (tripled) to second largest in Europe
 - Head of Corporate Planning (mid/long term Plan)
 - Member of the Corporate Sustainability Committee
 - Member of the Roche Anlage Commission (Pension Fund- CHF 12 bn)

Since retirement:

- Senior Adviser for McKinsey – worked on projects in several industries (IT, Transportation, Banking, and Healthcare sectors)- Capital Market Days, Equity story, Investor targeting, onboarding of CFOs and CEOs
- Invited as a conference speaker (Euronext IPO day, etc.)
- Advisor to two large European Cap Companies (Capital Market related)
- Chapter Lead on Investor Relations for the Conference Board (oldest non-profit think tank, based in Brussels)

Awards:

Best IR Professional ranked by the Buy and Sell side (26 times in 20 years)

Highlighted in the IR magazine as one of the top 30 in the past 30 years

First IR Professional inaugurated in the **Hall of Fame of Global Executives** in the Financial Market (2022- **Institutional Investor** and Extel Survey)

Included in the **Hall of Fame** by the **IR Magazine** (2024)

Institutional Investor and Extel Survey (audited by KPMG)